ArticleOncogenesis2014
Dual targeting of ErbB-2/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancer.
R Ghasemi et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
14 papers cite it
this papercites it